Tech Company Financing Transactions
Intercell AG Funding Round
Intercell AG closed a $50 million Series C venture capital round on 11/20/2003. Investors included MPM Capital.
Transaction Overview
Company Name
Announced On
11/20/2003
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
MPM Capital (Luke Evnin)
Proceeds Purpose
financing will be directed to accelerating the clinical development of our lead products: a therapeutic hepatitis C vaccine and a vaccine against Japanese encephalitis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Campus Vienna Biocenter 3
Vienna, 1030
Austria
Vienna, 1030
Austria
Phone
Website
Email Address
Overview
Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Lingelbach
Chief Financial Officer
Reinhard Kandera
VP - General Counsel
Phoebe Kornfeld
Browse more venture capital transactions:
Prev: 11/19/2003: CardioMEMS venture capital transaction
Next: 11/21/2003: Bay Microsystems venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs